Song Jiang Ma
Vorstandsvorsitzender bei Continent Pharmaceutical Inc.
Aktive Positionen von Song Jiang Ma
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | 01.07.2002 | - |
Vorstandsvorsitzender | 01.07.2002 | - | |
Beijing Jisheng Connor Network Technology Co. Ltd. | Direktor/Vorstandsmitglied | - | - |
Corporate Officer/Principal | - | - | |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | 20.01.2022 | - |
Vorstandsvorsitzender | 01.07.2011 | - | |
Corporate Officer/Principal | 01.07.2002 | 01.07.2011 |
Karriereverlauf von Song Jiang Ma
Ehemalige bekannte Positionen von Song Jiang Ma
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CATALYST BIOSCIENCES | Direktor/Vorstandsmitglied | 30.10.2023 | - |
Präsident | 30.10.2023 | - | |
Beijing Kangdini Factory | Gründer | 01.06.1996 | - |
Corporate Officer/Principal | 01.06.1996 | - | |
Beijing Jisheng Kangning Medical Technology Development | Direktor/Vorstandsmitglied | - | - |
Beijing Kangqiang Economic & Technical Co. Ltd. | Direktor/Vorstandsmitglied | - | - |
Beijing Institute of Telecommunication & Computer Applications | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Song Jiang Ma
China Electric Power Research Institute Ltd. | Graduate Degree |
Beijing University of Posts & Telecommunications | Undergraduate Degree |
Statistik
International
China | 10 |
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 8 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 8 |
---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
Beijing Jisheng Connor Network Technology Co. Ltd. | |
Beijing Institute of Telecommunication & Computer Applications | |
Beijing Jisheng Kangning Medical Technology Development | |
Beijing Kangqiang Economic & Technical Co. Ltd. | |
Beijing Kangdini Factory | |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Song Jiang Ma
- Erfahrung